Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Change in Acquisitions & Divestments: 2023-2025

Historic Change in Acquisitions & Divestments for InMed Pharmaceuticals (INM) over the last 2 years, with Sep 2025 value amounting to $20,957.

  • InMed Pharmaceuticals' Change in Acquisitions & Divestments fell 1.72% to $20,957 in Q3 2025 from the same period last year, while for Sep 2025 it was $41,903, marking a year-over-year decrease of 33.91%. This contributed to the annual value of $42,270 for FY2025, which is 0.45% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Change in Acquisitions & Divestments of $20,957 as of Q3 2025, which was up 839.35% from $2,231 recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Change in Acquisitions & Divestments registered a high of $21,324 during Q3 2024, and its lowest value of -$431 during Q2 2024.
  • Its 3-year average for Change in Acquisitions & Divestments is $13,164, with a median of $18,497 in 2025.
  • Over the last 5 years, InMed Pharmaceuticals' Change in Acquisitions & Divestments had its largest YoY gain of 617.63% in 2025, and its largest YoY loss of 24.34% in 2025.
  • InMed Pharmaceuticals' Change in Acquisitions & Divestments (Quarterly) stood at $21,317 in 2023, then climbed by 0.03% to $2,678 in 2024, then dropped by 1.72% to $20,957 in 2025.
  • Its last three reported values are $20,957 in Q3 2025, $2,231 for Q2 2025, and $16,037 during Q1 2025.